Physiologic coagulation system

The physiologic coagulation system is a highly coordinated biological cascade of proenzymes and cofactors that maintain vascular integrity by generating a stable fibrin clot at sites of endothelial damage (Palta et al., 2014, StatPearls). This system is traditionally divided into the extrinsic (tissue factor) and intrinsic (contact activation) pathways, which converge on the common pathway to activate Factor X and subsequently Thrombin (Factor IIa) (Gale, 2011, Journal of Thrombosis and Haemostasis). Thrombin serves as the central effector, converting soluble fibrinogen into insoluble fibrin polymers and activating platelets to reinforce the primary hemostatic plug (NIH, 2023). Pathological activation of this system leads to thromboembolic diseases such as deep vein thrombosis, pulmonary embolism, and ischemic stroke, while deficiencies in its components result in bleeding disorders like hemophilia (Versteeg et al., 2013, Physiological Reviews). Modern pharmacotherapy targets specific enzymes within this cascade—most notably Factor Xa and Thrombin—to provide anticoagulation for patients at risk of thrombosis (Connolly et al., 2009, NEJM). However, the therapeutic modulation of this system is inherently limited by the risk of major hemorrhage, as these pathways are also essential for normal wound healing (Schulman et al., 2003, NEJM).

Other names

Coagulation cascadeHemostatic systemBlood clotting systemClotting cascade

Anticoagulants function by inhibiting specific enzymes within the cascade, such as Factor Xa (e.g., rivaroxaban) or Thrombin (e.g., dabigatran), or by depleting functional Vitamin K-dependent factors (e.g., warfarin) (StatPearls, 2023; NIH, 2023).